Last 12 months
Inside the activity.
0 purchase rows · 12 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 9 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2025 Filed Feb 24, 2025 23:22 UTC |
Birkemeyer Elaine M.Chief Financial Officer
|
SaleCommon Stock | 3,778 | $14.70 | $55,538.11 |
DisclosureSEC source: 0001437749-25-004934 · rdgdoc.xml · nonDerivative · entry 4 Birkemeyer Elaine M. · CIK 0001968559 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,098 F4 · kind: Adoption date of referenced 10b5-1(c) plan is: 06-10-2024 F5 · shares: Consists of shares sold to cover taxes associated with the settlement of stock units. F6 · price: Reflects the weighted average price of 3,778 shares of common stock of Tactile Systems Technology, Inc. sold by the reporting person in multiple transactions on February 24, 2025 with sale prices ranging from $14.70 to $14.715 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:24 UTC |
REUVERS DANIEL L.Director
|
GrantCommon Stock | 15,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-004938 · rdgdoc.xml · nonDerivative · entry 1 REUVERS DANIEL L. · CIK 0001563602 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,880 F1 · shares: On February 22, 2023, the reporting person was granted performance stock units ("PSUs"), with one-third of such PSUs to be earned based on the extent to which certain performance conditions were met for a performance period of 2024. As determined on February 20, 2025, based on actual performance for 2024, the reporting person earned 15,853 PSUs. Those earned PSUs vested on February 20, 2025. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:23 UTC |
Burns KristieSr. VP Mktg & Clinical Affairs
|
GrantCommon Stock | 16,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-004936 · rdgdoc.xml · nonDerivative · entry 3 Burns Kristie · CIK 0001857721 · Sr. VP Mktg & Clinical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,838 F4 · shares: Represents restricted stock units ("RSUs") that vest as follows: one-third of the RSUs vest on each of the first three anniversaries of the grant date. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:23 UTC |
Burns KristieSr. VP Mktg & Clinical Affairs
|
GrantCommon Stock | 4,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-004936 · rdgdoc.xml · nonDerivative · entry 2 Burns Kristie · CIK 0001857721 · Sr. VP Mktg & Clinical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,259 F3 · shares: On February 21, 2024, the reporting person was granted PSUs, with one-third of such PSUs to be earned based on the extent to which certain performance conditions were met for a performance period of 2024. As determined on February 20, 2025, based on actual performance for 2024, the reporting person earned 4,131 PSUs. Those PSUs are scheduled to vest on the date in 2026 that the Compensation and Organization Committee determines the number of PSUs earned with respect to the 2025 performance year. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:23 UTC |
Burns KristieSr. VP Mktg & Clinical Affairs
|
GrantCommon Stock | 3,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-004936 · rdgdoc.xml · nonDerivative · entry 1 Burns Kristie · CIK 0001857721 · Sr. VP Mktg & Clinical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,128 F1 · shares: On February 22, 2023, the reporting person was granted performance stock units ("PSUs"), with one-third of such PSUs to be earned based on the extent to which certain performance conditions were met for a performance period of 2024. As determined on February 20, 2025, based on actual performance for 2024, the reporting person earned 3,359 PSUs. Those earned PSUs vested on February 20, 2025. F2 · balance_after: Includes 2,195 shares acquired on May 15, 2024 pursuant to the issuer's employee stock purchase plan. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:22 UTC |
Birkemeyer Elaine M.Chief Financial Officer
|
GrantCommon Stock | 36,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-004934 · rdgdoc.xml · nonDerivative · entry 3 Birkemeyer Elaine M. · CIK 0001968559 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,876 F3 · shares: Represents restricted stock units ("RSUs") that vest as follows: one-third of the RSUs vest on each of the first three anniversaries of the grant date. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:22 UTC |
Birkemeyer Elaine M.Chief Financial Officer
|
GrantCommon Stock | 6,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-004934 · rdgdoc.xml · nonDerivative · entry 2 Birkemeyer Elaine M. · CIK 0001968559 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,628 F2 · shares: On February 21, 2024, the reporting person was granted PSUs, with one-third of such PSUs to be earned based on the extent to which certain performance conditions were met for a performance period of 2024. As determined on February 20, 2025, based on actual performance for 2024, the reporting person earned 6,887 PSUs. Those PSUs are scheduled to vest on the date in 2026 that the Compensation and Organization Committee determines the number of PSUs earned with respect to the 2025 performance year. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:22 UTC |
Birkemeyer Elaine M.Chief Financial Officer
|
GrantCommon Stock | 3,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-004934 · rdgdoc.xml · nonDerivative · entry 1 Birkemeyer Elaine M. · CIK 0001968559 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,741 F1 · shares: On February 22, 2023, the reporting person was granted performance stock units ("PSUs"), with one-third of such PSUs to be earned based on the extent to which certain performance conditions were met for a performance period of 2024. As determined on February 20, 2025, based on actual performance for 2024, the reporting person earned 3,446 PSUs. Those earned PSUs vested on February 20, 2025. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:21 UTC |
King Laura G.Director
|
GrantCommon Stock | 2,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-004932 · rdgdoc.xml · nonDerivative · entry 1 King Laura G. · CIK 0002049487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,970 F1 · shares: Represents restricted stock units that will vest in a single installment on the earlier of the date of the Company's 2025 annual meeting of stockholders or the one year anniversary of the grant date. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:20 UTC |
Dodd Sheri LouiseDirector · Chief Executive Officer
|
GrantCommon Stock | 65,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-004930 · rdgdoc.xml · nonDerivative · entry 2 Dodd Sheri Louise · CIK 0001837111 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,390 F2 · shares: Represents restricted stock units ("RSUs") that vest as follows: one-third of the RSUs vest on each of the first three anniversaries of the grant date. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:20 UTC |
Dodd Sheri LouiseDirector · Chief Executive Officer
|
GrantCommon Stock | 20,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-004930 · rdgdoc.xml · nonDerivative · entry 1 Dodd Sheri Louise · CIK 0001837111 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,721 F1 · shares: On February 21, 2024, the reporting person was granted performance stock units ("PSUs"), with one-third of such PSUs to be earned based on the extent to which certain performance conditions were met for a performance period of 2024. As determined on February 20, 2025, based on actual performance for 2024, the reporting person earned 20,108 PSUs. Those PSUs are scheduled to vest on the date in 2026 that the Compensation and Organization Committee determines the number of PSUs earned with respect to the 2025 performance year. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:26 UTC |
Ferstler Sherri LeeSenior VP, Sales
|
SaleCommon Stock | 1,550 | $13.07 | $20,262.53 |
DisclosureSEC source: 0001437749-24-026833 · rdgdoc.xml · nonDerivative · entry 1 Ferstler Sherri Lee · CIK 0001987944 · Senior VP, Sales 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,764 F1 · shares: These shares were sold to cover taxes associated with the settlement of restricted stock units. F2 · price: Reflects the weighted average price of 1,550 shares of common stock of Tactile Systems Technology, Inc. sold by the reporting person in multiple transactions on August 12, 2024 with sale prices ranging from $13.05 to $13.30 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 22:42 UTC |
Dodd Sheri LouiseDirector · Chief Executive Officer
|
GrantCommon Stock | 64,959 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-025940 · rdgdoc.xml · nonDerivative · entry 1 Dodd Sheri Louise · CIK 0001837111 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,613 F1 · shares: Restricted stock unit award that vests as to one-third of the units on each of the first three anniversaries of the date of grant. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:36 UTC |
Birkemeyer Elaine M.Chief Financial Officer
|
SaleCommon Stock | 3,041 | $13.68 | $41,589.63 |
DisclosureSEC source: 0001437749-24-017675 · rdgdoc.xml · nonDerivative · entry 1 Birkemeyer Elaine M. · CIK 0001968559 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,295 F1 · shares: Consists of shares sold to cover taxes associated with the settlement of stock units. F2 · price: Reflects the weighted average price of 3,041 shares of common stock of Tactile Systems Technology, Inc. sold by the reporting person in multiple transactions on May 16, 2024 with sale prices ranging from $13.67 to $13.69 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:24 UTC |
BURKE WILLIAM WDirector
|
GrantCommon Stock | 10,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-016026 · rdgdoc.xml · nonDerivative · entry 2 BURKE WILLIAM W · CIK 0001200612 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,742 F2 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:24 UTC |
BURKE WILLIAM WDirector
|
SaleCommon Stock | 2,500 | $14.06 | $35,150.00 |
DisclosureSEC source: 0001437749-24-016026 · rdgdoc.xml · nonDerivative · entry 1 BURKE WILLIAM W · CIK 0001200612 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,273 F1 · shares: Adoption date of referenced 10b5-1(c) plan is: 06-13-2023 Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:24 UTC |
Asbury Valerie L.Director
|
GrantCommon Stock | 10,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-016025 · rdgdoc.xml · nonDerivative · entry 1 Asbury Valerie L. · CIK 0001904264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,744 F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:22 UTC |
Dodd Sheri LouiseDirector
|
GrantCommon Stock | 10,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-016022 · rdgdoc.xml · nonDerivative · entry 1 Dodd Sheri Louise · CIK 0001837111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,654 F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:22 UTC |
Huggenberger RaymondDirector
|
GrantCommon Stock | 10,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-016021 · rdgdoc.xml · nonDerivative · entry 1 Huggenberger Raymond · CIK 0001596078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,242 F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:21 UTC |
Shafer David BrentDirector
|
GrantCommon Stock | 10,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-016020 · rdgdoc.xml · nonDerivative · entry 1 Shafer David Brent · CIK 0001728374 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,744 F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:20 UTC |
Volkart Carmen BDirector
|
GrantCommon Stock | 10,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-016019 · rdgdoc.xml · nonDerivative · entry 1 Volkart Carmen B · CIK 0001282953 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,620 F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:20 UTC |
Washington Boyd VindellDirector
|
GrantCommon Stock | 10,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-016018 · rdgdoc.xml · nonDerivative · entry 1 Washington Boyd Vindell · CIK 0001994641 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,169 F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders. Read SEC document |
| May 06, 2024 Filed May 8, 2024 21:23 UTC |
Burns KristieSr. VP Mktg & Clinical Affairs
|
SaleCommon Stock | 815 | $14.37 | $11,712.77 |
DisclosureSEC source: 0001437749-24-015416 · rdgdoc.xml · nonDerivative · entry 1 Burns Kristie · CIK 0001857721 · Sr. VP Mktg & Clinical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,574 F1 · shares: Consists of shares sold to cover taxes associated with the settlement of stock units. F2 · price: Reflects the weighted average price of 815 shares of common stock of Tactile Systems Technology, Inc. sold by the reporting person in multiple transactions on May 6, 2024 with sale prices ranging from $14.37 to $14.39 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 01:43 UTC |
Burns KristieSr. VP Mktg & Clinical Affairs
|
SaleCommon Stock | 243 | $15.25 | $3,705.87 |
DisclosureSEC source: 0001437749-24-006206 · rdgdoc.xml · nonDerivative · entry 2 Burns Kristie · CIK 0001857721 · Sr. VP Mktg & Clinical Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,389 F5 · shares: Consists of shares sold to cover taxes associated with the settlement of stock units, which sales were pursuant to a Rule 10b5-1 instructions on February 25, 2021. F6 · shares: Adoption date of referenced 10b5-1(c) plan is: 02-24-2022. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 01:42 UTC |
REUVERS DANIEL L.Director · President and CEO
|
SaleCommon Stock | 1,396 | $15.25 | $21,289.00 |
DisclosureSEC source: 0001437749-24-006205 · rdgdoc.xml · nonDerivative · entry 2 REUVERS DANIEL L. · CIK 0001563602 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,027 F3 · shares: Consists of shares sold to cover taxes associated with the settlement of stock units, which sales were pursuant to Rule 10b5-1 instructions on February 25, 2021. F4 · shares: Adoption date of referenced 10b5-1(c) plan is: 02-24-2022. Read SEC document |
| February 27, 2024 Filed Mar 1, 2024 01:43 UTC |
Burns KristieSr. VP Mktg & Clinical Affairs
|
SaleCommon Stock | 1,091 | $15.58 | $17,001.16 |
DisclosureSEC source: 0001437749-24-006206 · rdgdoc.xml · nonDerivative · entry 1 Burns Kristie · CIK 0001857721 · Sr. VP Mktg & Clinical Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,632 F1 · shares: Consists of shares sold to cover taxes associated with the settlement of stock units, which sales were pursuant to a Rule 10b5-1 instructions on February 24, 2022. F2 · shares: Adoption date of referenced 10b5-1(c) plan is: 02-24-2022. F3 · price: Reflects the weighted average price of 1,091 shares of common stock of Tactile Systems Technology, Inc. sold by the reporting person in multiple transactions on February 27, 2024 with sale prices ranging from $15.5707 to $15.615 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F4 · balance_after: Includes 1,211 shares acquired under the Company's employee stock purchase plan on November 15, 2023. Read SEC document |
| February 27, 2024 Filed Mar 1, 2024 01:42 UTC |
REUVERS DANIEL L.Director · President and CEO
|
SaleCommon Stock | 4,689 | $15.60 | $73,148.40 |
DisclosureSEC source: 0001437749-24-006205 · rdgdoc.xml · nonDerivative · entry 1 REUVERS DANIEL L. · CIK 0001563602 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,423 F1 · shares: Consists of shares sold to cover taxes associated with the settlement of stock units, which sales were pursuant to Rule 10b5-1 instructions on February 24, 2022. F2 · shares: Adoption date of referenced 10b5-1(c) plan is: 02/24/2022. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 02:13 UTC |
REUVERS DANIEL L.Director · President and CEO
|
SaleCommon Stock | 6,239 | $15.81 | $98,644.83 |
DisclosureSEC source: 0001437749-24-005784 · rdgdoc.xml · nonDerivative · entry 4 REUVERS DANIEL L. · CIK 0001563602 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 244,112 F6 · shares: Consists of shares sold to cover taxes associated with the settlement of stock units, which sales were pursuant to Rule 10b5-1 instructions on February 25, 2021 and February 24, 2022. F7 · price: Reflects the weighted average price of 6,239 shares of common stock of Tactile Systems Technology, Inc. sold by the reporting person in multiple transactions on February 26, 2024 with sale prices ranging from $15.79 to $15.875 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 02:12 UTC |
Burns KristieSr. VP Mktg & Clinical Affairs
|
SaleCommon Stock | 2,015 | $15.91 | $32,048.58 |
DisclosureSEC source: 0001437749-24-005783 · rdgdoc.xml · nonDerivative · entry 4 Burns Kristie · CIK 0001857721 · Sr. VP Mktg & Clinical Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,512 F6 · shares: Consists of shares sold to cover taxes associated with the settlement of stock units, which sales were pursuant to Rule 10b5-1 instructions on February 25, 2021 and February 24, 2022. Read SEC document |
| February 24, 2024 Filed Feb 28, 2024 02:13 UTC |
REUVERS DANIEL L.Director · President and CEO
|
GrantCommon Stock | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-005784 · rdgdoc.xml · nonDerivative · entry 3 REUVERS DANIEL L. · CIK 0001563602 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 250,351 F5 · shares: On February 22, 2023, the reporting person was granted PSUs, with the number of PSUs earned to be determined based on the extent to which certain performance conditions are met for a performance period consisting of three separate performance years of 2023, 2024 and 2025. As determined on February 24, 2024, based on actual performance for 2023, the reporting person earned 13,100 PSUs with respect to the 2023 performance year. Those PSUs are scheduled to vest on the date in 2025 that the Compensation and Organization Committee determines the number of PSUs earned with respect to the 2024 performance year. Read SEC document |
| February 24, 2024 Filed Feb 28, 2024 02:13 UTC |
REUVERS DANIEL L.Director · President and CEO
|
GrantCommon Stock | 44,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-005784 · rdgdoc.xml · nonDerivative · entry 2 REUVERS DANIEL L. · CIK 0001563602 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,251 F4 · shares: On February 24, 2022, the reporting person was granted performance stock units ("PSUs"), with the number of PSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2023. As determined on February 24, 2024, based on actual performance for 2023, the reporting person earned 44,930 PSUs. Of those earned PSUs, one-third, or 14,977 PSUs, vested on February 24, 2024, and the remaining two-thirds, or 29,953 PSUs, are scheduled to vest on February 24, 2025. Read SEC document |
| February 24, 2024 Filed Feb 28, 2024 02:12 UTC |
Burns KristieSr. VP Mktg & Clinical Affairs
|
GrantCommon Stock | 2,776 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-005783 · rdgdoc.xml · nonDerivative · entry 3 Burns Kristie · CIK 0001857721 · Sr. VP Mktg & Clinical Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,527 F5 · shares: On February 22, 2023, the reporting person was granted PSUs, with the number of PSUs earned to be determined based on the extent to which certain performance conditions are met for a performance period consisting of three separate performance years of 2023, 2024 and 2025. As determined on February 24, 2024, based on actual performance for 2023, the reporting person earned 2,776 PSUs with respect to the 2023 performance year. Those PSUs are scheduled to vest on the date in 2025 that the Compensation and Organization Committee determines the number of PSUs earned with respect to the 2024 performance year. Read SEC document |
| February 24, 2024 Filed Feb 28, 2024 02:12 UTC |
Burns KristieSr. VP Mktg & Clinical Affairs
|
GrantCommon Stock | 8,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-005783 · rdgdoc.xml · nonDerivative · entry 2 Burns Kristie · CIK 0001857721 · Sr. VP Mktg & Clinical Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,751 F4 · shares: On February 24, 2022, the reporting person was granted performance stock units ("PSUs"), with the number of PSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2023. As determined on February 24, 2024, based on actual performance for 2023, the reporting person earned 8,986 PSUs. Of those earned PSUs, one-third, or 2,995 PSUs, vested on February 24, 2024, and the remaining two-thirds, or 5,991 PSUs, are scheduled to vest on February 24, 2025. Read SEC document |
| February 24, 2024 Filed Feb 28, 2024 02:10 UTC |
Birkemeyer Elaine M.Chief Financial Officer
|
GrantCommon Stock | 2,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-005782 · rdgdoc.xml · nonDerivative · entry 1 Birkemeyer Elaine M. · CIK 0001968559 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,336 F1 · shares: On May 10, 2023, the reporting person was granted performance stock units ("PSUs"), with the number of PSUs earned to be determined based on the extent to which certain performance conditions are met for a performance period consisting of three separate performance years of 2023, 2024 and 2025. As determined on February 24, 2024, based on actual performance for 2023, the reporting person earned 2,848 PSUs with respect to the 2023 performance year. Those PSUs are scheduled to vest on the date in 2025 that the Compensation and Organization Committee determines the number of PSUs earned with respect to the 2024 performance year. Read SEC document |
| February 23, 2024 Filed Feb 28, 2024 02:13 UTC |
REUVERS DANIEL L.Director · President and CEO
|
SaleCommon Stock | 5,378 | $14.85 | $79,852.54 |
DisclosureSEC source: 0001437749-24-005784 · rdgdoc.xml · nonDerivative · entry 1 REUVERS DANIEL L. · CIK 0001563602 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,321 F1 · shares: Consists of shares sold to cover taxes associated with the settlement of stock units, which sales were pursuant to a Rule 10b5-1 instruction on February 22, 2023. F2 · shares: Adoption date of referenced 10b5-1(c) plan is: 02-22-2023. F3 · price: Reflects the weighted average price of 5,378 shares of common stock of Tactile Systems Technology, Inc. sold by the reporting person in multiple transactions on February 23, 2024 with sale prices ranging from $14.84 to $14.89 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 23, 2024 Filed Feb 28, 2024 02:12 UTC |
Burns KristieSr. VP Mktg & Clinical Affairs
|
SaleCommon Stock | 2,249 | $14.80 | $33,278.00 |
DisclosureSEC source: 0001437749-24-005783 · rdgdoc.xml · nonDerivative · entry 1 Burns Kristie · CIK 0001857721 · Sr. VP Mktg & Clinical Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,765 F1 · shares: Consists of shares sold to cover taxes associated with the settlement of stock units, which sales were pursuant to a Rule 10b5-1 instruction on February 22, 2023. F2 · shares: Adoption date of referenced 10b5-1(c) plan is: 02-22-2023. F3 · price: Reflects the weighted average price of 2,249 shares of common stock of Tactile Systems Technology, Inc. sold by the reporting person in multiple transactions on February 23, 2024 with sale prices ranging from $14.7911 to $14.82 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 21, 2024 Filed Feb 24, 2024 01:25 UTC |
REUVERS DANIEL L.Director · President and CEO
|
GrantCommon Stock | 72,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-005438 · rdgdoc.xml · nonDerivative · entry 1 REUVERS DANIEL L. · CIK 0001563602 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,699 F1 · shares: The restricted stock units ("RSUs") vest as follows: one-third of the RSUs vest on each of the first three anniversaries of the grant date. Read SEC document |
| February 21, 2024 Filed Feb 24, 2024 01:24 UTC |
Burns KristieSr. VP Mktg & Clinical Affairs
|
GrantCommon Stock | 19,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-005437 · rdgdoc.xml · nonDerivative · entry 1 Burns Kristie · CIK 0001857721 · Sr. VP Mktg & Clinical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,014 F1 · shares: The restricted stock units ("RSUs") vest as follows: one-third of the RSUs vest on each of the first three anniversaries of the grant date. Read SEC document |
| February 21, 2024 Filed Feb 24, 2024 01:22 UTC |
Ferstler Sherri LeeSenior VP, Sales
|
GrantCommon Stock | 21,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-005436 · rdgdoc.xml · nonDerivative · entry 1 Ferstler Sherri Lee · CIK 0001987944 · Senior VP, Sales 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,314 F1 · shares: The restricted stock units ("RSUs") vest as follows: one-third of the RSUs vest on each of the first three anniversaries of the grant date. Read SEC document |
| February 21, 2024 Filed Feb 24, 2024 01:22 UTC |
Birkemeyer Elaine M.Chief Financial Officer
|
GrantCommon Stock | 32,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-005435 · rdgdoc.xml · nonDerivative · entry 1 Birkemeyer Elaine M. · CIK 0001968559 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,488 F1 · shares: The restricted stock units ("RSUs") vest as follows: one-third of the RSUs vest on each of the first three anniversaries of the grant date. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 22:00 UTC |
Washington Boyd VindellDirector
|
GrantCommon Stock | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-031676 · rdgdoc.xml · nonDerivative · entry 1 Washington Boyd Vindell · CIK 0001994641 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,700 F1 · shares: Represents restricted stock units that will vest in a single installment on the earlier of one year from the grant date or the date of the Company's 2024 annual meeting of stockholders. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 23:08 UTC |
Ferstler Sherri LeeSenior VP, Sales
|
GrantCommon Stock | 18,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-023381 · rdgdoc.xml · nonDerivative · entry 1 Ferstler Sherri Lee · CIK 0001987944 · Senior VP, Sales 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,701 F1 · shares: Restricted stock unit award that vests as to one-third of the units on each of the first three anniversaries of the date of grant. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 20:10 UTC |
REUVERS DANIEL L.Director · President and CEO
|
SaleCommon Stock | 1,062 | $20.53 | $21,807.64 |
DisclosureSEC source: 0001437749-23-022794 · rdgdoc.xml · nonDerivative · entry 1 REUVERS DANIEL L. · CIK 0001563602 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,653 F1 · shares: Consists of shares sold to cover taxes associated with the settlement of stock units. F2 · price: Reflects the weighted average price of 1,062 shares of common stock of Tactile Systems Technology, Inc. sold by the reporting person in multiple transactions on August 7, 2023 with sale prices ranging from $20.5304 to $20.56 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2023 Filed May 16, 2023 21:52 UTC |
BURKE WILLIAM WDirector
|
SaleCommon Stock | 4,400 | $21.86 | $96,184.00 |
DisclosureSEC source: 0001437749-23-014844 · rdgdoc.xml · nonDerivative · entry 1 BURKE WILLIAM W · CIK 0001200612 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,773 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 05/27/2022. Read SEC document |
| May 10, 2023 Filed May 11, 2023 20:22 UTC |
Birkemeyer Elaine M.Chief Financial Officer
|
GrantCommon Stock | 29,068 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-013954 · rdgdoc.xml · nonDerivative · entry 1 Birkemeyer Elaine M. · CIK 0001968559 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,068 F1 · shares: The restricted stock units ("RSUs") vest as follows: one-third of the RSUs vest on each of the first three anniversaries of the grant date. Read SEC document |
| May 08, 2023 Filed May 10, 2023 20:30 UTC |
BURKE WILLIAM WDirector
|
GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-013634 · rdgdoc.xml · nonDerivative · entry 1 BURKE WILLIAM W · CIK 0001200612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,173 F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders. Read SEC document |
| May 08, 2023 Filed May 10, 2023 20:32 UTC |
Asbury Valerie L.Director
|
GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-013640 · rdgdoc.xml · nonDerivative · entry 1 Asbury Valerie L. · CIK 0001904264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,275 F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders. Read SEC document |
| May 08, 2023 Filed May 10, 2023 20:29 UTC |
Dodd Sheri LouiseDirector
|
GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-013630 · rdgdoc.xml · nonDerivative · entry 1 Dodd Sheri Louise · CIK 0001837111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,185 F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders. Read SEC document |
| May 08, 2023 Filed May 10, 2023 20:26 UTC |
Huggenberger RaymondDirector
|
GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-013626 · rdgdoc.xml · nonDerivative · entry 1 Huggenberger Raymond · CIK 0001596078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,773 F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders. Read SEC document |
| May 08, 2023 Filed May 10, 2023 20:23 UTC |
Shafer David BrentDirector
|
GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-013622 · rdgdoc.xml · nonDerivative · entry 1 Shafer David Brent · CIK 0001728374 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,275 F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.